MDxHealth Gears Up For Major EU Growth
Executive Summary
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
You may also be interested in...
MDxHealth Prostate Cancer Test Identifies Increased Risk of Cancer Recurrence
MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).
MDxHealth expects to be key Dutch provider of urine-based prostate cancer testing
MDxHealth has launched a new liquid biopsy prostate cancer test, SelectMDx, in Europe, a month after gaining the technology through the acquisition of its developer NovioGendix. The test will be offered through NovioGendix’s lab facilities in Nijmegen, the Netherlands, which MDxHealth also acquired.